RxFINE-Low Breast Cancer Trial Has Launched

The study evaluates if chemotherapy is necessary for patients with high anatomic but low genomic risk breast cancer.

Updated on Sept. 24, 2026 in Cancer

RxFINE-Low Breast Cancer Trial Has Launched

Live Poll

Should medical treatments prioritize tumor biology testing to reduce unnecessary chemotherapy for breast cancer patients?

The ECOG-ACRIN Cancer Research Group launched the RxFINE-Low (EA1242) trial to determine if chemotherapy provides additional clinical benefit to specific high-risk breast cancer patients. Sponsored by the National Cancer Institute, the study seeks to see if tumor biology can guide treatment to spare patients from chemotherapy-related toxicities.

Why it matters

By analyzing whether tumor biology can effectively guide treatment, the trial aims to reduce unnecessary exposure to harsh side effects for patients who may not require adjuvant chemotherapy. Findings from the research could eventually inform future insurance coverage policies for genomic testing.

The study targets postmenopausal women and men with ER+/HER2- breast cancer, focusing on those with tumors over 5 cm or involvement in more than 3 lymph nodes. Participants are randomized 1:1 to receive either chemotherapy plus ribociclib or endocrine therapy with ribociclib alone.

The players

ECOG-ACRIN Cancer Research Group

This is a member-supported national organization that designs and conducts cancer research in adult patients.

National Cancer Institute

Part of the National Institutes of Health, this agency coordinates the federal government's cancer research efforts.

Novartis Pharmaceuticals Corporation

This global healthcare company develops and manufactures various pharmaceutical products and medical treatments.

The details

Researchers will follow approximately 2,000 participants for up to 10 years to track long-term recurrence and survival rates. The trial specifically evaluates patients with an Oncotype DX Breast Recurrence Score between 0 and 25 to see if genomic risk profiles can safely dictate care plans.

September 24, 2026: The RxFINE-Low trial officially launched.
10 years: Researchers will monitor participants for the duration of the follow-up period.

Cancer
Sept. 18
FDA Approved New Breast Cancer Combination Therapy
Cancer
Sept. 24
Vaccine Misinformation Threatened Cancer Treatment Progress
Cancer
Sept. 22
U.S. Cancer Death Rates Have Continued to Decline

The Big Picture

This study follows a pattern established by the National Cancer Institute's National Clinical Trials Network to integrate genomic profiling into standardized treatment protocols.

Patients meeting the criteria may have the opportunity to participate in a trial that could potentially eliminate the need for adjuvant chemotherapy. This could spare individuals from significant treatment-related toxicities while maintaining the standard of care for long-term health.

The takeaway

The RxFINE-Low study represents a growing shift toward de-escalating cancer treatments for patients with favorable genomic profiles. Patients should discuss with their oncologists whether their tumor's genomic risk score makes them suitable candidates for current or future clinical research.